Warren Peters, MD, MPH, FOMADirector – Metabolic Obesity Research Clinic (MORC)Associate Professor LOMA LINDA UNIVERSITY – School of Public Health From Dopamine Pills to Personalized Neurons: Aspen’s Autologous Cell Therapy for Parkinson’s Disease Parkinson’s disease (PD) has long been managed through pharmacology: levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and complex delivery systems designed to… Continue reading Personalized Cell Replacement for Parkinson’s
Category: Voice of Health
Why Caregiving Feels Impossible
Warren Peters, MD, MPH, FOMADirector – Metabolic Obesity Research Clinic (MORC)Associate ProfessorLOMA LINDA UNIVERSITY – School of Public HealthNutrition Research Center When you care for someone with Alzheimer’s, Parkinson’s, ALS, FTD, or Huntington’s, something quietly devastating happens…you start losing control of your life too.” “They’re losing abilities.You’re losing stability.And every day becomes a shifting landscape… Continue reading Why Caregiving Feels Impossible
How Friendships Keep Us Sharp
Actionable Ways to Build and Maintain Mind-Sharpening Friendships If you’re finding your social circle shrinking, leveraging your passion for digital tools can actually be the key to expanding it: 1. Join Niche Online Groups: Use platforms like Meetup or Facebook to find groups centered around your specific interests, such as GenAI” or “Local History Buffs.”… Continue reading How Friendships Keep Us Sharp
New Approach in Parkinson’s
LRRK2 PROTAC (ARV-102): From Target Degradation to Biomarker-Driven Trials LRRK2 PROTAC (ARV-102): From Target Degradation to Biomarker-Driven Trials Curator: Warren Peters, MD, MPH, FOMA Silo: Voice of Health – Research Edition Research Summary ARV-102 is a proteolysis-targeting chimera (PROTAC) that binds LRRK2 and recruits an E3 ligase, tagging the protein for degradation. Unlike traditional kinase… Continue reading New Approach in Parkinson’s
Removing a Problem Protein
A New Approach in Parkinson’s: Removing a Problem Protein (LRRK2) A New Approach in Parkinson’s: Removing a Problem Protein Silo: Voice of Health – Patient Edition What’s Being Studied Scientists are testing a new therapy called ARV-102. It helps cells identify and remove a protein called LRRK2 that may contribute to Parkinson’s. The first trial… Continue reading Removing a Problem Protein
What the GLP-1 Shift Means
Healthspan Is Becoming Real: What the GLP-1 Shift Means Healthspan Is Becoming Real: What the GLP-1 Shift Means At a leading aging research meeting, major drug makers described GLP-1 medicines as “longevity therapeutics.” That language shift matters: it opens the door to earlier prevention trials, better biomarkers, and treatments that aim to help us live… Continue reading What the GLP-1 Shift Means
Healthspan Is Becoming Real
Healthspan Is Becoming Real: What the GLP-1 Shift Means Healthspan Is Becoming Real: What the GLP-1 Shift Means At a leading aging research meeting, major drug makers described GLP-1 medicines as “longevity therapeutics.” That language shift matters: it opens the door to earlier prevention trials, better biomarkers, and treatments that aim to help us live… Continue reading Healthspan Is Becoming Real
Working Together for Better Alzheimer’s Care
Working Together for Better Alzheimer’s Care: The ADRC Team Approach Working Together for Better Alzheimer’s Care Source: Akter S, Bawa EM, Riccardi N, et al. Journal of Alzheimer’s Disease Reports. 2025;9. doi:10.1177/25424823251385902 Silo: Voice of Health (Patient Edition) Why “Team Science” Matters Alzheimer’s affects memory, independence, and families. No single expert can solve it alone.… Continue reading Working Together for Better Alzheimer’s Care
GLP-1 Trial Maintains Motor Function in Parkinson’s Disease
Citation: Athauda D et al., 2025, New England Journal of Medicine, DOI 10.1056/NEJMoa2306791Research Summary:A randomized double-blind Phase 2 trial evaluated lixisenatide, a GLP-1 receptor agonist, in 156 individuals Participants received lixisenatide or placebo over 12 months. The lixisenatide group maintained stable with a decline in the placebo group. Gastrointestinal effects were the most common adverse… Continue reading GLP-1 Trial Maintains Motor Function in Parkinson’s Disease
Harnessing Team Science
Team Science for Dementia: The ADRC Circular Loop (Discovery → Development → Delivery → Dissemination) Harnessing Team Science in Dementia Research: The ADRC Circular Loop Citation: Akter S, Bawa EM, Riccardi N, et al. Journal of Alzheimer’s Disease Reports. 2025;9. doi:10.1177/25424823251385902 Curator: Warren Peters, MD MPH FOMA • Silo: Voice of Health (Research Edition) SEO… Continue reading Harnessing Team Science